The optimal therapy for children with relapsed or refractory acute promyelocytic leukemia (APL) is unclear. We therefore reviewed our institutional outcomes for children undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for advanced APL. Between 1986 and 2003, 12 allogeneic HSCTs (five related donor, seven unrelated donor) were performed for 11 patients (median age, 13 years) with relapsed (n ¼ 8) or refractory (n ¼ 3) APL. All patients engrafted, after a median of 18.5 days. Grade B-D acute graft-versus-host disease (GVHD) developed after five transplants (42%; 90% CI, 18-68%), and the cumulative incidence of chronic GVHD was 45% (90% CI, 19-71%). The cumulative incidence of overt relapse post-HSCT was 10% (90% CI, 0-28%). The overall 5-year survival was 73% (90% confidence interval (CI), 51-95%), with a median post-HSCT followup of 64 months. The Lansky/Karnofsky performance scores are 100% in six of eight survivors. In view of the low risk of subsequent relapse and favorable survival suggested by other reports and our own experience, we continue to recommend allogeneic HSCT for children with advanced APL for whom a suitably HLA-matched donor is identified.
Acute promyelocytic leukemia (APL) is a rare disease in childhood, accounting for 5-12% of pediatric acute myeloid leukemia (AML). [1] [2] [3] Most cases are associated with a balanced translocation, t (15;17) , that leads to the fusion of the promyelocytic (PML) and retinoic acid receptor (RAR)-a genes. 4 Since the advent of all-trans retinoic acid (ATRA) use in these patients, more than 70% of adults and children presenting with de novo APL have had sustained disease-free survival with chemotherapy alone. 5, 6 For relapsed APL, remission reinduction rates of more than 80% have been reported with contemporary therapy, and sustained second remissions have been obtained with consolidation therapy consisting of either chemotherapy (including ATRA), arsenic trioxide, autologous hematopoietic stem cell transplantation (HSCT), or allogeneic HSCT. [7] [8] [9] [10] [11] [12] However, the indications for one form of consolidation therapy over another remain unclear, and these studies have overwhelmingly addressed adult patients.
In view of the paucity of published data relating to allogeneic HSCT for relapsed or refractory APL in childhood, we reviewed our institutional experience to determine outcomes among this population.
Material and methods

Patient and transplant characteristics
Between 1986 and 2003, 12 allogeneic HSCTs were performed for 11 subjects with relapsed (n ¼ 8) or refractory induction-failure (n ¼ 3) APL at our institution. Data were collected by retrospective chart and database review, with approval of the Institutional Review Board. Table 1 summarizes the disease characteristics of the patients, and details of previous therapy. The diagnosis of APL was made by morphologic criteria in all cases, with cytogenetic confirmation in the eight subjects diagnosed after 1990. Table 2 summarizes transplant characteristics and outcomes. All transplants were performed with myeloablative conditioning therapy. In seven of the 12 transplants, a radiation-based regimen was employed. For five transplants, the marrow graft was obtained from an HLAmatched relative; for seven, the graft was obtained from an unrelated donor (five HLA-matched URD marrow grafts, one HLA-matched URD peripheral blood stem cell graft, and one single-antigen HLA-mismatched cord blood graft). All patients received cyclosporine and short-course methotrexate for graft-versus-host disease (GVHD) prophylaxis, 13 except Patients 1, 2, and 3, in whom methotrexate alone was used. Patients 5, 8, 10 , and 11 additionally received methylprednisolone from days 7 to 21.
14 Recipients who were seropositive for herpes simplex virus received acyclovir prophylaxis from day À5 through day 24. If the donor or recipient was cytomegalovirus seropositive, as was the case in seven of the 12 transplants, high-dose acyclovir prophylaxis was administered. 15 Acute GVHD (Grade B or greater) was treated with intravenous methylprednisolone (2-3 mg/kg/day). Higher doses of corticosteroids, antithymocyte globulin, and/or tacrolimus were used to treat steroid-resistant GVHD in some cases. Chronic GVHD was treated with cyclosporine and prednisone, and additional immunosuppressive agents were added in refractory cases.
Outcomes and statistical analysis
The primary outcome was survival. Secondary outcomes were engraftment (defined as the first of three consecutive days of an absolute neutrophil count X0.5 Â 10 9 /l; the date of platelet recovery was the first of three consecutive days with a platelet count X50 Â 10 9 /l), acute and chronic GVHD, 16, 17 relapse (defined as overt hematologic or extramedullary relapse), transplant-related mortality, and performance status among survivors. Methods for molecular testing for PML/RAR-a transcripts were developed at our institution in 1998. However, given the lack of published data regarding the clinical utility of 'surveillance' molecular testing after allogeneic HSCT for APL, we have not routinely followed our patients' molecular status. Indeed, molecular testing on bone marrow was performed in only one patient post transplant (Patient 11). Post transplant relapse was defined exclusively as overt hematologic or extramedullary relapse. Performance status of all survivors except Patient 7 was assessed within 6 months of submission of this report, using the Lansky (for children p12 years of age) or Karnofsky performance scores. 18 Patient 7 was lost to follow-up 35 months post transplant, and her performance status at that time is noted in Table 2 . Review of the medical records and database was completed in January 2004.
The overall survival was estimated by the method of Kaplan and Meier, with 90% confidence intervals (CIs) based on Greenwood's formula. Patients were censored at the time they were last known to be alive. Rates of relapse and chronic GVHD were calculated by the method of cumulative incidence, identifying transplant-related mortality as a competing risk.
Results
A total of 12 allogeneic HSCTs were performed at our institution in 11 pediatric patients with relapsed or refractory APL between 1986 and 2003. The outcomes of these transplants are summarized in Table 2 . The median post transplant follow-up of survivors is 64 months (range, 12-207 months).
Engraftment, GVHD, and relapse
All patients engrafted, with a median time to neutrophil recovery of 18.5 days (range, 12-32 days). Platelet recovery occurred at a median of 32 days (range, 17-64 þ days). Patient 5 died without recovering platelets on day 64.
Acute GVHD developed after six transplants (58%, 90% CI 32-82%), with Grades B-D seen in five cases (42%, 90% CI 18-68%). The cumulative incidence of chronic GVHD was 45% (90% CI, 19-72%). Chronic GVHD was limited in three patients (Patients 2, 4, and 8), and extensive in two (Patients 1 and 3) .
One patient (Patient 9) relapsed in the marrow 14 months after HLA-matched related donor (MRD) HSCT, yielding a cumulative incidence of overt post transplant relapse of 10% (90% CI, 0-28%). Patient 9 is currently alive and relapse-free 24 months after a second allogeneic HSCT using an unrelated donor. Molecular testing for PML/ RAR-a transcripts in the marrow was performed post transplant in one patient: Patient 11, who had been molecularly positive immediately pre-transplant, was molecularly negative when tested 12 months post transplant.
Survival
For the 11 patients, probability of survival at 5 years post-HSCT was 73% (90% CI, 51-95%). No patient died with APL. The three deaths were attributed to early transplantrelated complications. Thus, transplant-related mortality was 27% (90% CI, 8-56%). Patient 4 died 162 days post-HSCT from respiratory failure, secondary to viral pneumonia. Patient 5 died 64 days post-HSCT from pulmonary aspergillosis. Patient 7 died 147 days post-HSCT from respiratory failure due to regimen-related diffuse alveolar damage. The median performance score among seven survivors with recent follow-up was 100% (range 80-100%). Patient 2 had a performance score of 100% at the time she was lost to follow-up.
Discussion
We report a favorable outcome among children undergoing allogeneic HSCT for relapsed and refractory APL at our institution, with a probability of survival at 5 years of 73%. Four of five patients who were not in hematologic remission at the time of transplant are disease-free survivors.
There is a broad range of published outcomes after allogeneic HSCT for relapsed APL. The 11 adult patients reported by Thomas et al 9 had a median disease-free survival of only 8 months after MRD HSCT. However, Sanz et al 8 documented 6-year overall survival of 58% among 127 patients (median age, 33 years) receiving allografts for APL in second remission. Transplant-related mortality in this group of patients was 33%, but the low relapse rate, at 15%, was identical to that observed among patients undergoing allogeneic HSCT for APL in first remission. Recently, Lo-Coco et al 12 reported disease-free survival of 46% among 17 patients (two under 18 years of age) receiving MRD allografts for advanced APL; transplant-related mortality was 32%. Importantly, these investigators demonstrated that allogeneic HSCT may effectively treat patients with persistent minimal residual disease: of six patients testing positive for PML/RAR-a transcripts pre-HSCT, four converted to negative soon after HSCT, and two became negative following cyclosporine withdrawal. This contrasts with the extraordinarily high risk of post transplant relapse among patients positive for PML/RAR-a transcripts in the marrow immediately prior to autologous HSCT. 7 It is this potential for affording a potent graft-versus-leukemia effect that is the greatest asset of an allogeneic HSCT in this setting.
It is important to note that our own experience, and the published experience referenced herein, relates to many patients initially treated in the pre-ATRA era. It is possible that the absence of prior exposure to ATRA may have improved the outcome of relapsing patients treated with ATRA. In addition, our report suffers the weaknesses inherent in a retrospective review of a relatively small number of subjects. Confidence intervals are necessarily broad, and potentially relevant subgroup analyses cannot be performed. The question of optimal therapy for advanced APL will only be resolved by a randomized study. However, until such a study has been conducted, the superior protection from relapse afforded by allogeneic HSCT, and the favorable survival suggested by our experience, will lead us to continue to recommend allogeneic HSCT for children with relapsed or refractory APL for whom a suitable donor can be identified.
